Current Headlines

  1. Advances In MALDI Mass Spectrometry Within Drug Discovery
    12/28/2017

    Collectively, the articles in the December 2017 special issue of SLAS Discovery on Advances in MALDI Mass Spectrometry within Drug Discovery present a snapshot of innovation in the MALDI application space as it stands recently

  2. Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC For Treatment Of All Forms Of Primary Hyperoxaluria
    12/7/2017

    Dicerna Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, recently announced the dosing of the first human in DCR-PHXC-101, a Phase 1 clinical trial of DCR-PHXC, the Company’s most advanced GalXC product candidate

  3. Vedanta Biosciences Announces Initiation Of Phase 1a/1b Trial For New Drug Class Of Rationally-Defined Bacterial Consortia Derived From The Human Microbiome
    12/7/2017

    Vedanta Biosciences, an affiliate of PureTech Health developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortium of human microbiome-derived bacteria, recently announced the initiation of a Phase 1a/1b, first-in-human, clinical trial of VE303, the Company’s lead, orally-administered microbiome therapeutic product candidate for recurrent Clostridium difficile infection (rCDI)

  4. Morphotek To Present Its Proprietary RESPECT™ Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego
    12/7/2017

    Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present its Residue-Specific Conjugation Technology (RESPECT) at the Antibody Engineering & Therapeutics conference being held December 11-15 at the Manchester Grand Hyatt in San Diego, California

  5. Synaffix Launches toxSYN, A New Platform Of ADC Payloads
    12/6/2017

    Synaffix BV, a biotechnology company that has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates (ADCs), recently announced the launch of a new platform of highly potent cytotoxic ADC payloads that will be integrated into its existing ADC platform

  6. Sunovion Receives FDA Approval For Lonhala Magnair Inhalation Solution To Treat COPD
    12/6/2017

    Sunovion Pharmaceuticals Inc. (Sunovion) recently announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Lonhala Magnair(glycopyrrolate) Inhalation Solution (25 mcg twice daily), also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Sunovion expects LONHALA MAGNAIR to be available in U.S. pharmacies in early 2018

  7. Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response Of CA4P With Checkpoint Inhibitor
    12/5/2017

    Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced new preliminary data in a mouse model of colon cancer indicating that reductions in tumor volume after treatment with CA4P and anti-CTLA-4 combination therapy are associated with an enhanced immune response

  8. Omni Health Announced Development Of New Drug Candidate
    12/5/2017

    Omni Health, Inc., (OTC: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and biotech engineering, today announced its plan already in motion to create a drug candidate compelling to Big Pharma

  9. Ncardia And Evotec Entered A Licencing Agreement For Disease Modelling Using iPS Cells
    12/4/2017

    Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced recently that they entered into a global non-exclusive IP licensing agreement with Evotec

  10. Blue Oak And PsychoGenics Announce A Drug Discovery Partnership
    12/4/2017

    Blue Oak Pharmaceuticals, Inc. (Blue Oak) and PGI Drug Discovery LLC (PsychoGenics), recently announced that they have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions